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Le
the
MaOnPAR—the Online Partnership to Accelerate Research—seeks to provide a second opportunity for funding of high-quality,
unfunded applications originally submitted to the National Institutes of Health and other national and international
funding agencies. OnPAR will match applicable, unfunded applications with the research priorities of nongovernment
organizations such as private biomedical foundations, pharmaceutical companies, venture capital funds, and other private
funds. Funding organization members will review and make ﬁnal funding decisions through a simple, 2-step process
whereby applicants can submit public abstracts directly to OnPAR. If a member requests additional information, then, by
invitation only, an applicant can submit their original unfunded application and their peer review summary statement.
Advancing research discovery and drug development to improve clinical outcomes for patients afﬂicted with or at risk for
disease is the primary goal of OnPAR. OnPAR invites the scientiﬁc community to fully participate in this new funding
paradigm by submitting their National Institutes of Health public abstracts so that funding members can review and
potentially support these high-quality, unfunded applications. (J Am Coll Cardiol Basic Trans Science 2016;1:536–40)
© 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).E ach year, hundreds of innovative, high-scoringresearch applications are left unfunded.Currently, global funding agencies fund <25%
of the research applications they receive. In 2015, the
National Institutes of Health (NIH), the largest source
of funding for medical research in the world, reviewed
69,973 applications and funded 14,457, for an average
funding rate of 20.7% (1). The funding rates vary signif-
icantly, depending on the disease area (2). The top NIH
institutes, in terms of applications received, funded
between 13% and 29.6% of applications (Table 1). As
shown in Table 1, the overall funding rate for National
Heart, Lung, and Blood Institute was 21.9%; however,
the funding rate for Research Project Grants (R01)
was only 13.0% (3). This leaves many outstanding
cardiovascular research projects unfunded. Thesem the Leidos Life Sciences, Frederick, Maryland. Mr. Dueñas is the Dir
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nuscript received August 25, 2016; accepted August 25, 2016.unfunded projects now have a second opportunity
for funding through the Online Partnership to Accel-
erate Research (OnPAR), which will be described in
the following text.
The primary goal of OnPAR is to connect funders
with unfunded research applications. OnPAR, which
launched ofﬁcially in March 2016 (4,5), seeks to match
quality biomedical research applications with the
priority areas of interest of private foundations,
pharmaceutical and biotech companies, and/or other
private biomedical research funders.
Government, private foundations, family founda-
tions, pharmaceutical companies, venture capital
funds, and other funds for biomedical research are
part of a funding ecosystem that supports glo-
bal biomedical research. Their goal is to supportector of the Health Research Management Practice,
eidos Life Sciences. Both authors have reported that
.
TABLE 1 2015 Funding Statistics for the Top 5 NIH Institutes
NIH
Institute
Number of
Applications
Reviewed
Number of
Applications
Awarded
Number of
Unfunded
Applications Award Amount
Success
Rate
Unfunded
Rate
NCI 9,513 1,236 8,277 $508,125,718 13.0% 87.0%
NIAID 5,932 1,272 4,660 $577,320,121 21.4% 78.6%
NHLBI 4,233 928 3,305 $497,923,174 21.9% 78.1%
NINDS 3,992 819 3,173 $310,868,609 20.5% 79.5%
NIGMS 3,626 1,074 2,552 $404,894,040 29.6% 70.4%
Total 27,296 5,329 21,967 $2,299,131,662
Data from the National Institutes of Health (2).
NCI ¼ National Cancer Institute; NHLBI ¼ National Heart, Lung, and Blood Institute; NIAID ¼ National Institute
of Allergy and Infectious Disease; NIGMS ¼ National Institute of General Medicine Sciences; NIH ¼ National
Institutes of Health; NINDS ¼ National Institute of Neurological Disorders and Stroke.
AB BR E V I A T I O N S
AND ACRONYM S
ALS = amyotrophic lateral
sclerosis
CDA = Conﬁdential Disclosure
Agreement
COPD = chronic obstructive
pulmonary disease
HIV/AIDS = human
immunodeﬁciency virus/
acquired immune deﬁciency
syndrome
NCI = National Cancer Institute
NHLBI = National Heart, Lung,
and Blood Institute
NIAID = National Institute of
Allergy and Infectious Disease
NIGMS = National Institute of
General Medicine Sciences
NIH = National Institutes of
Health
NINDS = National Institute of
Neurological Disorders and
Stroke
OnPAR = Online Partnership to
Accelerate Research
TB = tuberculosis
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537research and drug development for the advancement
of public health. Over the last decade, these organi-
zations have begun working together to build on their
complementary strengths. OnPAR is a new funding
paradigm that seeks to build public-private partner-
ships within the funding ecosystem.
HOW DOES OnPAR WORK?
OnPAR will rely on 3 pillars that support the entire
research enterprise: applicants, members, and part-
ners (Figure 1).
Applicants will submit their abstracts and applica-
tion material for consideration by members. Members
will consider those applications for funding. Partners
will inform high-scoring, unfunded applicants about
OnPAR after applications are peer-reviewed and ﬁnal
funding decisions are made.
APPLICANTS
Applicants represent the key to unlocking the success
of the OnPAR public-private partnership. OnPAR will
succeed as long as applicants submit their abstracts
and application materials for review to further
accelerate research discovery and development.
The beneﬁt for applicants is simple. Researchers can
spend months generating preliminary data and pre-
paring the necessary documents (including a robust
research strategy, detailed budget, and other re-
quirements) for their proposal. Even if this proposal is
well conceived, it may not be selected for funding (6).
Application success rates vary by disease area, as stated
previously, as well as by type of application (Table 2).
For applicants across all grant mechanisms, there
is no cost to submit application materials to OnPAR.
It should take no more than 5 to 10 min to register and
enter a public abstract.
The abstract submission is a simple 2-step process:
1. Registration: the applicant enters basic information
to register for OnPAR access.
2. Abstract submission: the applicant submits the
same “public” abstract that was submitted with the
NIH application.
After the abstract is submitted, it is “matched,” if
applicable, with the research priority areas of OnPAR
members. At their own discretion, each member may
request additional information if interested in
reviewing the application.
If a member requests additional information, then,
by invitation only, OnPAR will ask for a:
1. Full application: this should be the exact same
application that was submitted to NIH.2. Summary statement: this is the peer review
evaluation received for the application.
3. Conﬁdentiality/nondisclosure agreement:
OnPAR will execute a conﬁdentiality or
nondisclosure agreement that will protect
the applicant’s intellectual property.
Applicants will know who is interested in
reviewing their application.
WHO IS ELIGIBLE?. All applicants that have
submitted NIH applications in 2015 and 2016
may submit their unfunded applications to
OnPAR right now. Applicants that scored
within the 30th percentile for all NIH regular
submissions, 50th percentile for all rare dis-
eases, or were highly scored (for those that
are not ranked) are eligible to submit their
abstracts to OnPAR. See details about eligi-
bility on the OnPAR web site (4).
Eventually, OnPAR hopes to accept appli-
cation materials from other national and in-
ternational funding agencies, and discussions
are in progress. The OnPAR website has
recently been upgraded to facilitate submis-
sion from all funding agencies, and all ab-
stracts must be submitted in English.SHOULD I SUBMIT AN APPLICATION NOW EVEN
IF I DO NOT SEE A MEMBER THAT MATCHES MY
SPECIFIC RESEARCH AREA? Yes. OnPAR will be
adding new members in the coming weeks and
months. The more abstracts OnPAR receives in any
research topic, the greater the incentive for a research
member to join the partnership. Submission to
OnPAR does not preclude reapplying to NIH. There
are no limitations on disease or topic area; abstracts
in any disease area will be accepted. Examples
include cancers, cardiovascular-related diseases,
Alzheimer’s disease, Parkinson’s disease, diabetes,
TABLE 2
Me
Research g
Small bus
researc
Small bus
transfe
Training g
Data from
fundingfact
FIGURE 1 OnPAR Pillars to Success
OnPAR ¼ Online Partnership to Accelerate Research.
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538epilepsy, dementia, alopecia areata, malaria, tuber-
culosis, human immunodeﬁciency virus/acquired
immune deﬁciency syndrome, chronic obstructive
pulmonary disease, celiac disease, lupus, arthritis,
multiple sclerosis, cystic ﬁbrosis, muscular dystro-
phy, and amyotrophic lateral sclerosis; as well as rare
diseases such as Duchenne muscular dystrophy, pro-
gressive supranuclear palsy, epidermolysis bullosa,
Friedreich’s ataxia, cystinosis, Niemann-Pick type C1
disease, and all those included in the National Orga-
nization for Rare Disorders member list (7).
OnPAR is free for applicants, and abstract and
application materials are simple to submit. OnPAR
offers a second opportunity to receive funding
without rewriting a completely new application.
Although applicants may not receive full funding of
their research efforts, they may receive a small bridge
award. The member funding strategies are described
in the following text.Example of 2015 NIH Success Rates by Select Grant Mechanisms
chanism Activity Success Rate Unfunded Rate
rants All (in aggregate) 18.3% 81.7%
iness innovative
h grants
All (in aggregate) 18.1% 81.9%
iness technology
r grants
All (in aggregate) 18.0% 82.0%
rants All (in aggregate) 28.9% 71.1%
the National Institutes of Health (NIH) (https://report.nih.gov/fundingfacts/
s.aspx).MEMBERS
Members are the second pillar of OnPAR, and they are
ready to open the door of opportunity to many
exceptional, but unfunded, research projects.
OnPAR is relying on its members to fund these
high-quality, unfunded research applications. Mem-
bers might be private biomedical foundations or
charities, pharmaceutical companies, venture capital
funds, or other nongovernment private funds. Mem-
bers will fund applications that best ﬁt their mission
and research priority areas. Some members will fund
through OnPAR in addition to their own funding
mechanisms. Others might eventually consider
funding through OnPAR only, thereby reducing their
investment in peer review and other administrative
activities.
Current OnPAR members can be found on the
OnPAR web site (4). Leidos will be announcing new
members over the next few months.
Members might fund unfunded applications at
different levels, depending on their needs. Funding
strategies include:
 Fully funding an application: if there is a gap in the
member portfolio and it meets their research
priority areas.
 Partially funding an application: if 1 or more of the
aims of the application address a gap in their
portfolio.
 Bridge funding: if the work is an innovative or
ongoing project that could beneﬁt from a few more
experiments before resubmitting to the NIH.
All members will follow their own guidelines for
funding, and awards will be made through a grant or
contract mechanism.
 Grants are more likely if applications involve work
in early discovery or translational research. Such
efforts might be funded by a private foundation or
charity member, although pharmaceutical com-
panies might also provide grants.
 Contracts are more likely to be used by a pharma-
ceutical or venture capital fund where royalties or
a licensing agreement might be possible. Private
foundations sometimes fund contracts as well.
Members review abstracts and request full appli-
cation materials for applicants that meet their
research priority areas and address gaps in their
portfolio. There is no minimum requirement for any
member to fund any number of applications. How-
ever, all members have expressed interest and see
OnPAR as a catalyst to accelerate research, ﬁnd cures,
and develop treatments.
FIGURE 2 OnPAR Process: From NIH Submission to Potential Funding by an
OnPAR Member
CDA ¼ conﬁdential disclosure agreement; NIH ¼ National Institutes of Health; OnPAR ¼
Online Partnership to Accelerate Research.
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Partners are the third pillar of the new OnPAR funding
paradigm. They provide the infrastructure for OnPAR
to obtain fully peer-reviewed research applications.
Due to the proprietary nature of the materials,
partners are prohibited from sharing unfunded ap-
plications with OnPAR. However, partners can inform
applicants about this new funding paradigm so that
the scientiﬁc community can submit their applica-
tions directly to OnPAR. Details on how to submit
application materials can be found on the OnPAR
web site (4).
Currently, OnPAR works only with the NIH, its
funding partner, and the agency plays a critical role in
OnPAR. The NIH, a part of the U.S. Department of
Health and Human Services, is the nation’s medical
research agency, andmakes important discoveries that
improve health and save lives. The NIH is the largest
source of funding for medical research in the world,
and its mission is to seek fundamental knowledge
about the nature and behavior of living systems and
the application of that knowledge to enhance health,
lengthen life, and reduce illness and disability.
Leidos works closely with the NIH Ofﬁce of Extra-
mural Programs to ensure that all NIH Program Ofﬁ-
cers are up to date about OnPAR. The NIH Ofﬁce of
Extramural Programs provides leadership and exper-
tise in science program management, including
program and policy development, interpretation, co-
ordination, oversight, evaluation, training, and
outreach, for the extramural research community and
NIH extramural staff. Such efforts promote and sus-
tain the capability of the highest-quality research and
training programs to improve public health.
The NIH Program Ofﬁcers’ role is to inform eligible
research applicants about OnPAR. Soon after advisory
councils meet and ﬁnal funding decisions are made
(the NIH standard dates are available online [8]),
Program Ofﬁcers inform high-scoring applicants
about OnPAR.
As the third pillar of OnPAR, the NIH and all future
partners are essential to its success. Partners prepare
and announce research programs, train applicants
and reviewers on the submission and review of
research applications, and make ﬁnal funding
decisions. Their goal is to support research discovery
and development for the advancement of public
health. However, they cannot fund all worthy
research projects; subsequently, research advance-
ment may be hindered. OnPAR was created to ﬁll the
gap in funding and, in doing so, accelerate research
discovery and development.New partners will be joining soon, expanding
OnPAR at the national and international level and
providing a second funding opportunity for quality
unfunded applications.
OnPAR will be successful with the support of its 3
pillars: applicants, members, and partners. Each pillar
plays a critical role in the research enterprise to
accelerate discoveries that affect public health. The
process from submission to NIH to potential funding
by an OnPAR member is shown in Figure 2. The
OnPAR funding process might take 3 to 6 months,
depending on each member. As members get more
comfortable with this new funding process, the
funding cycle may narrow.
Biomedical research is the nexus of the research
enterprise that comprises the academic and patient
community, industry, foundation, private funders,
and government. As the editors of JACC: Basic to
Translational Science stated in the inaugural issue of
this journal, “translational science exempliﬁes ‘big
science’ because it requires effective cooperation
between basic and clinical investigators in academia
and industry, patients and their families, patient
advocacy groups, and governmental funding and
regulatory agencies to evaluate and develop new
therapies. No one person can possibly acquire all
the requisite skills needed to conduct this type of
research, and no one individual can move their
ideas forward in the cardiovascular [or any other
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540disease] space unaided” (9). OnPAR seeks to become a
funding platform, a forum, and a learning center for
multidisciplinary, multistakeholder collaboration to
advance research discovery and drug development.
OnPAR will seek to fund all types of research, from
early discovery and basic research through trans-
lational and clinical research. Please join us in making
OnPAR a successful new research-funding paradigmto advance research and ﬁnd cures and treatments for
the many diseases affecting our communities,
including cardiovascular disease.
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